EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
Status:
Completed
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
The aim of the study is to investigate the safety and efficacy of empagliflozin versus
placebo on top of guideline-directed medical therapy in patients with heart failure with
reduced ejection fraction.